微生物组疗法市场－全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争格局划分，2021-2031年预测

全球微生物组疗法市场将从2025年的1.9711亿美元成长到2031年的10.1318亿美元，复合年增长率达31.37%。微生物组疗法是一类生物药物，旨在透过调控人体微生物组（包括细菌、真菌和病毒群落）来恢復微生物平衡，从而治疗或预防疾病。

主要市场驱动因素

监管审批的增加和对活体生物治疗产品的有利指导方针是推动市场从实验研究走向商业化的主要催化剂。新型疗法的成功核准验证了微生物组修復的科学原理，增强了研发者的信心，并促进了其在临床上的应用。

主要市场挑战

复杂的监管环境是限制全球微生物组疗法市场成长的一大障碍。与传统的小分子药物不同，微生物组疗法是由活的、异质性的生物混合物组成，这在生产一致性、稳定性以及效力验证方面都带来了独特的挑战。

主要市场趋势

将微生物组疗法整合为免疫肿瘤佐剂正迅速成为关键趋势，其驱动力在于特定微生物菌株能够调节宿主免疫系统并克服对免疫检查点抑制剂的抗药性。研发人员正日益关注协同组合疗法，其中活体生物治疗产品能够激活肿瘤微环境，从而增强现有癌症免疫疗法（如PD-1/PD-L1阻断剂）的疗效。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球微生物组疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（粪菌移植与微生物组药物）
  • 依申请（艰难梭菌感染、克隆氏症、发炎性肠道疾病、糖尿病、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美微生物组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲微生物组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区微生物组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲微生物组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲微生物组疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球微生物组疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• 4D Pharma plc
• Enterome SA
• Finch Therapeutics Group, Inc.
• Vedanta Bioscience, Inc.
• Seres Therapeutics, Inc.
• Microbiotica Limited
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings Co., Ltd.
• AOBiome Therapeutics, Inc.
• Ferring Pharmaceuticals SA

第十六章：策略建议

第17章调查会社について・免责事项

The Global Microbiome Therapeutics Market will grow from USD 197.11 Million in 2025 to USD 1013.18 Million by 2031 at a 31.37% CAGR. Microbiome therapeutics are a class of biological drugs designed to manipulate the human microbiome, comprising communities of bacteria, fungi, and viruses, to treat or prevent disease by restoring microbial balance.

Key Market Drivers

Increasing regulatory approvals and favorable guidelines for live biotherapeutic products act as a primary catalyst, transitioning the market from experimental research to commercial viability. The successful authorization of novel therapies validates the underlying science of microbiome restoration, encouraging developer confidence and clinical adoption. This shift is evident in the tangible revenue streams now generated by recently approved assets, which underscores the growing market uptake of these treatments.

Key Market Challenges

The complex regulatory landscape stands as a formidable barrier hampering the growth of the Global Microbiome Therapeutics Market. Unlike traditional small-molecule drugs, microbiome therapeutics consist of living, heterogeneous biological mixtures that present unique difficulties regarding manufacturing consistency, stability, and potency verification. The absence of standardized global guidelines for characterizing these live biotherapeutic products creates significant ambiguity for developers, who must navigate undefined pathways for clinical trial design and safety evaluation. This uncertainty directly stifles market expansion by inflating research costs and extending development timelines, making it difficult for companies to secure the necessary capital for late-stage commercialization.

Key Market Trends

The Integration of Microbiome Therapeutics as Immuno-Oncology Adjuvants is rapidly gaining traction as a pivotal trend, driven by the ability of specific microbial strains to modulate the host immune system and overcome resistance to checkpoint inhibitors. Developers are increasingly focusing on synergistic combinations where live biotherapeutic products prime the tumor microenvironment, thereby enhancing the efficacy of existing cancer immunotherapies like PD-1/PD-L1 blockers. This approach is moving beyond early-stage concepts into robust clinical validation, targeting difficult-to-treat solid tumors.

Key Market Players

• 4D Pharma plc
• Enterome SA
• Finch Therapeutics Group, Inc.
• Vedanta Bioscience, Inc.
• Seres Therapeutics, Inc.
• Microbiotica Limited
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings Co., Ltd.
• AOBiome Therapeutics, Inc.
• Ferring Pharmaceuticals SA

Report Scope:

In this report, the Global Microbiome Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Microbiome Therapeutics Market, By Type:

• FMT v/s Microbiome Drugs

Microbiome Therapeutics Market, By Application:

• C. Difficile
• Crohn's Disease
• Inflammatory Bowel Disease
• Diabetes
• Others

Microbiome Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Microbiome Therapeutics Market.

Available Customizations:

Global Microbiome Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Microbiome Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (FMT v/s Microbiome Drugs)
  • 5.2.2. By Application (C. Difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Microbiome Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Microbiome Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Microbiome Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Microbiome Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Microbiome Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Microbiome Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Microbiome Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Microbiome Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Microbiome Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Microbiome Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Microbiome Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Microbiome Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Microbiome Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Microbiome Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Microbiome Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Microbiome Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Microbiome Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Microbiome Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Microbiome Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Microbiome Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Microbiome Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Microbiome Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Microbiome Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Microbiome Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Microbiome Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. 4D Pharma plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Enterome SA
• 15.3. Finch Therapeutics Group, Inc.
• 15.4. Vedanta Bioscience, Inc.
• 15.5. Seres Therapeutics, Inc.
• 15.6. Microbiotica Limited
• 15.7. Destiny Pharma plc
• 15.8. Taisho Pharmaceutical Holdings Co., Ltd.
• 15.9. AOBiome Therapeutics, Inc.
• 15.10. Ferring Pharmaceuticals SA

16. Strategic Recommendations

17. About Us & Disclaimer